FDA approves first oral treatment for moderately to severely active Cr

FDA has approved Rinvoq (upadacitinib) for adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. Rinvoq is the first approved oral product available to treat moderately to severely active Crohn’s…

#fda #rinvoq #crohn #nct03345849 #cdai #janus